Therefore, in this study, we explored the intrinsic impacts of the PD-L1 expression status on postoperative recurrence in patients with surgically resected EGFR-mutated lung adenocarcinoma, stratified by each stage of the disease, utilizing follow-up data predating adjuvant osimertinib and atezolizumab. The gene discussed is EGFR; the disease is lung adenocarcinoma.